ConductScience.org, home

Paper10075615

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Moreland LW and 18 others. Ann Intern Med, 1999. Cited by 1,195 papers, by iCite.

Cite this record

ConductScience Library. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Papers, record 10075615. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10075615

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
PubMed
Journal
Ann Intern Med
PubMed
Year
1999
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1,195
iCite
Relative citation ratio, by iCite
31.7
iCite
Revised in PubMed
2022-04-09
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Moreland LWL W
2Schiff MHM H
3Baumgartner SWS W
4Tindall EAE A
5Fleischmann RMR M
6Bulpitt KJK J
7Weaver ALA L
8Keystone ECE C
9Furst DED E
10Mease PJP J
11Ruderman EME M
12Horwitz DAD A
13Arkfeld DGD G
14Garrison LL
15Burge DJD J
16Blosch CMC M
17Lange MLM L
18McDonnell NDN D
19Weinblatt MEM E

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Inflammatory Agents, Non-SteroidalMajor topic
Arthritis, RheumatoidMajor topic
Immunoglobulin GMajor topic
Receptors, Tumor Necrosis FactorMajor topic
Algorithms
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Etanercept
Female
Humans
Male
Middle Aged
Patient Dropouts
Quality of Life
Recombinant Proteins
Statistics as Topic

Source PubMed

Download CSV of topics

Cited by343

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,195 citations.

PMIDTitleJournalYearIn PapersSource
42864407Computational design and translational development of TCR-mimic scFv antibodies for peptide-HLA neoantigen targeting.NPJ Drug Discov2026https://conductscience.org/library/papers/42864407PubMed
42104019De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.Exp Mol Med2026https://conductscience.org/library/papers/42104019PubMed
41733787Role of macrophages and dendritic cells in autoimmune diseases: a specific focus on tumor necrosis factor targeting therapies against rheumatoid arthritis.Mol Biol Rep2026https://conductscience.org/library/papers/41733787PubMed
40836173Transforming rheumatoid arthritis care: dynamic budget impact models with ACR to DAS28 mapping for anti-TNFs, JAK inhibitors, and interleukins.Clin Rheumatol2025https://conductscience.org/library/papers/40836173PubMed
40091354Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis.Innate Immun2025https://conductscience.org/library/papers/40091354PubMed
39802551Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update.Rheumatol Immunol Res2024https://conductscience.org/library/papers/39802551PubMed
38827788Different modalities to manage rheumatoid arthritis: an A to Z story.Future Sci OA2024https://conductscience.org/library/papers/38827788PubMed
38479734Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA.BMJ Open2024https://conductscience.org/library/papers/38479734PubMed
37371813Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center.Biomedicines2023https://conductscience.org/library/papers/37371813PubMed
36836166Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy.J Clin Med2023https://conductscience.org/library/papers/36836166PubMed
36497082The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling.Cells2022https://conductscience.org/library/papers/36497082PubMed
36355537A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.Pharmaceuticals (Basel)2022https://conductscience.org/library/papers/36355537PubMed
35322865Piceatannol suppresses inflammation and promotes apoptosis in rheumatoid arthritis‑fibroblast‑like synoviocytes by inhibiting the NF‑κB and MAPK signaling pathways.Mol Med Rep2022https://conductscience.org/library/papers/35322865PubMed
35003068Toward Overcoming Treatment Failure in Rheumatoid Arthritis.Front Immunol2021https://conductscience.org/library/papers/35003068PubMed
34429666Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension.J Exp Pharmacol2021https://conductscience.org/library/papers/34429666PubMed
34148193A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.Rheumatol Ther2021https://conductscience.org/library/papers/34148193PubMed
33800290The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics.Int J Mol Sci2021https://conductscience.org/library/papers/33800290PubMed
33569512Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future.Genes Dis2021https://conductscience.org/library/papers/33569512PubMed
33441191Long-term remission and biologic persistence rates: 12-year real-world data.Arthritis Res Ther2021https://conductscience.org/library/papers/33441191PubMed
33399862Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.Cardiovasc Res2021https://conductscience.org/library/papers/33399862PubMed

See all 343 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/10075615

GET https://conductscience.org/api/papers/v1/10075615/cited_by?page=2